Bio & Pharma
S.Korea's Medicox boosts unit for oral insulin, medical cannabis
The company will issue convertible bonds worth $32 million with three financial entities
By Dec 29, 2022 (Gmt+09:00)
1
Min read
Most Read
Deutsche Bank's Korea IB head quits after country head resigns
Hanwha buys S’pore Dyna-Mac’s stake for $73.8 mn from Keppel
Macquarie Korea Asset Management confirms two nominees
Meritz leaves door open for an M&A, to stay shareholder friendly
Korea's Taeyoung to sell local hotel to speed up debt workout
South Korea's Medicox Co. on Wednesday said it will raise 40 billion won ($32 million) to boost its unit for oral insulin and cannabidiol (CBD).
The company will issue convertible bonds worth 40 billion won through Meritz Securities, Now Investment and L-Bio Production Activation Equity No. 1.
The funds will pay for Oramed Pharmaceuticals of Israel to conduct clinical trials for oral insulin and get licensing in Korea. To expand its bio operations, Medicox said it will set up a think tank as an affiliate and actively develop and invest in new state-of-the-art drugs related to CBD.
Write to Jeong Min Nam, at peux@hankyung.com
More to Read
Comment 0
LOG IN